Clinical trial
Lenalidomide and Docetaxel in Treating Patients With Advanced Solid Tumors
NCT00253344 · Case Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00253344 |
|---|---|
| Title | Lenalidomide and Docetaxel in Treating Patients With Advanced Solid Tumors |
| Official title | Phase I Trial of Daily Lenalidomide (CC-5013, Revlimid™) and Docetaxel Given Every Three Weeks in Patients With Advanced Solid Tumors |
| Lead sponsor | Case Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | docetaxel, lenalidomide |
| Enrollment | 33 |
| Start date | Jun 1, 2005 |
| Primary completion | Jan 1, 2008 |
| Completion | Jun 1, 2008 |
| First posted | Nov 15, 2005 |
| Last update posted | Jun 11, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: